197 related articles for article (PubMed ID: 31315671)
1. Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity.
Schuelke MR; Wongthida P; Thompson J; Kottke T; Driscoll CB; Huff AL; Shim KG; Coffey M; Pulido J; Evgin L; Vile RG
J Immunother Cancer; 2019 Jul; 7(1):188. PubMed ID: 31315671
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.
Chastkofsky MI; Pituch KC; Katagi H; Zannikou M; Ilut L; Xiao T; Han Y; Sonabend AM; Curiel DT; Bonner ER; Nazarian J; Horbinski CM; James CD; Saratsis AM; Hashizume R; Lesniak MS; Balyasnikova IV
Clin Cancer Res; 2021 Mar; 27(6):1766-1777. PubMed ID: 33272983
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma.
Mendez F; Kadiyala P; Nunez FJ; Carney S; Nunez FM; Gauss JC; Ravindran R; Pawar S; Edwards M; Garcia-Fabiani MB; Haase S; Lowenstein PR; Castro MG
Clin Cancer Res; 2020 Aug; 26(15):4080-4092. PubMed ID: 32332014
[TBL] [Abstract][Full Text] [Related]
5. Targeting of the alpha
Cobb DA; de Rossi J; Liu L; An E; Lee DW
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210306
[TBL] [Abstract][Full Text] [Related]
6. Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets.
Aziz-Bose R; Monje M
Curr Opin Oncol; 2019 Nov; 31(6):522-530. PubMed ID: 31464759
[TBL] [Abstract][Full Text] [Related]
7. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas.
Laspidea V; Puigdelloses M; Labiano S; Marrodán L; Garcia-Moure M; Zalacain M; Gonzalez-Huarriz M; Martínez-Vélez N; Ausejo-Mauleon I; de la Nava D; Herrador-Cañete G; Marco-Sanz J; Guruceaga E; de Andrea CE; Villalba M; Becher O; Squatrito M; Matía V; Gállego Pérez-Larraya J; Patiño-García A; Gupta S; Gomez-Manzano C; Fueyo J; Alonso MM
JCI Insight; 2022 Apr; 7(7):. PubMed ID: 35393952
[TBL] [Abstract][Full Text] [Related]
8. Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models.
Martinez-Velez N; Marigil M; García-Moure M; Gonzalez-Huarriz M; Aristu JJ; Ramos-García LI; Tejada S; Díez-Valle R; Patiño-García A; Becher OJ; Gomez-Manzano C; Fueyo J; Alonso MM
Acta Neuropathol Commun; 2019 Apr; 7(1):64. PubMed ID: 31036068
[TBL] [Abstract][Full Text] [Related]
9. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
10. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
11. Local Delivery of OncoVEX
Moesta AK; Cooke K; Piasecki J; Mitchell P; Rottman JB; Fitzgerald K; Zhan J; Yang B; Le T; Belmontes B; Ikotun OF; Merriam K; Glaus C; Ganley K; Cordover DH; Boden AM; Ponce R; Beers C; Beltran PJ
Clin Cancer Res; 2017 Oct; 23(20):6190-6202. PubMed ID: 28706012
[No Abstract] [Full Text] [Related]
12. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.
Gállego Pérez-Larraya J; Garcia-Moure M; Labiano S; Patiño-García A; Dobbs J; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; Puigdelloses M; Laspidea V; Astigarraga I; Lopez-Ibor B; Cruz O; Oscoz Lizarbe M; Hervas-Stubbs S; Alkorta-Aranburu G; Tamayo I; Tavira B; Hernandez-Alcoceba R; Jones C; Dharmadhikari G; Ruiz-Moreno C; Stunnenberg H; Hulleman E; van der Lugt J; Idoate MÁ; Diez-Valle R; Esparragosa Vázquez I; Villalba M; de Andrea C; Núñez-Córdoba JM; Ewald B; Robbins J; Fueyo J; Gomez-Manzano C; Lang FF; Tejada S; Alonso MM
N Engl J Med; 2022 Jun; 386(26):2471-2481. PubMed ID: 35767439
[TBL] [Abstract][Full Text] [Related]
14. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
[TBL] [Abstract][Full Text] [Related]
15. Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma.
Price G; Bouras A; Hambardzumyan D; Hadjipanayis CG
EBioMedicine; 2021 Jul; 69():103453. PubMed ID: 34157482
[TBL] [Abstract][Full Text] [Related]
16. Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors.
Wongthida P; Schuelke MR; Driscoll CB; Kottke T; Thompson JM; Tonne J; Stone C; Huff AL; Wetmore C; Davies JA; Parker AL; Evgin L; Vile RG
Neuro Oncol; 2020 Dec; 22(12):1757-1770. PubMed ID: 32459315
[TBL] [Abstract][Full Text] [Related]
17. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
18. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.
Martínez-Vélez N; Garcia-Moure M; Marigil M; González-Huarriz M; Puigdelloses M; Gallego Pérez-Larraya J; Zalacaín M; Marrodán L; Varela-Guruceaga M; Laspidea V; Aristu JJ; Ramos LI; Tejada-Solís S; Díez-Valle R; Jones C; Mackay A; Martínez-Climent JA; García-Barchino MJ; Raabe E; Monje M; Becher OJ; Junier MP; El-Habr EA; Chneiweiss H; Aldave G; Jiang H; Fueyo J; Patiño-García A; Gomez-Manzano C; Alonso MM
Nat Commun; 2019 May; 10(1):2235. PubMed ID: 31138805
[TBL] [Abstract][Full Text] [Related]
19. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
